On Monday 22 June 2020 representatives from the
pharmaceutical and chemical industries will be giving evidence to
the House of Lords EU Goods Sub-Committee’s inquiry on how to
facilitate future UK-EU trade in manufactured
goods.
This session will be held remotely and streamed
on Parliament
TV.
At 10.30am the Committee will hear
from:
-
Dr Louise Gill, Head of Policy, Global Regulatory
Affairs, GlaxoSmithKline
-
Richard Ayton, Director of Government Affairs, Dow
Chemical UK and Ireland.
Possible questions that may be asked by the Committee
include:
-
How will non-tariff barriers affect the
pharmaceutical and chemical industries at the end of the
transition period? How costly could they be?
-
What steps have you taken to prepare for the end of
the transition period? Is there anything the Government could
do to support businesses in their
preparations?
-
How important is formal UK-EU regulatory
cooperation for your businesses and what specific regulatory
provisions would you like to see in the UK-EU trade
agreement?
-
How important is UK-EU cooperation on market
surveillance and what form should this take?
-
What unilateral measures could the UK take to
reduce the regulatory barriers to UK-EU trade in the
pharmaceutical and chemical sectors?
On Tuesday 26 May 2020 the Committee invited written
contributions to this inquiry. Click
here to read the full call for evidence and find out how
to submit evidence.